Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03331393 · ClinicalTrials.gov registry record

The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis

A clinical trial of Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb.

Completed
Registry status
265
Enrollment target
7
Study locations

NCT03331393: Completed study of Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb.

NCT03331393 is a study of Rheumatoid Arthritis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 265 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (94% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03331393, a study of Rheumatoid Arthritis, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
265 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to investigate the value of Orencia in rapidly progressing Rheumatoid Arthritis (RA).

Conditions Studied

Rheumatoid Arthritis

Interventions

  • OTHER Non-interventional

Study Locations (7)

California

  • Local Institution - Beverly Hills

Georgia

  • Local Institution - 0005 - Gainesville

Idaho

  • Local Institution - Coeur d'Alene

Minnesota

  • Local Institution - 0007 - Eagan

North Carolina

  • Medication Management, LLC - Greensboro

South Carolina

  • Local Institution - Myrtle Beach

Washington

  • Local Institution - Richland

Trial Details

FieldValue
Enrollment Target 265 participants
Start Date 2017-03-16
Est. Completion 2019-01-17
Bristol-Myers Squibb

1,025 total trials

What the finished NCT03331393 record still lists

NCT03331393 is an observational study that tracks outcomes without assigning an intervention. The registered 265 participants enrollment target is mid-sized for trials with a published cap, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Non-interventional is the first listed.

NCT03331393 lists 7 locations in 7 states (California, Georgia, Idaho).

Frequently Asked Questions

What is clinical trial NCT03331393 about?

NCT03331393 is a clinical study titled "The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis". The purpose of this study is to investigate the value of Orencia in rapidly progressing Rheumatoid Arthritis (RA).

What is the current status of trial NCT03331393?

This trial is currently completed. The enrollment target is 265 participants. The study started on 2017-03-16. Estimated completion is 2019-01-17.

What conditions does trial NCT03331393 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT03331393?

The interventions under investigation include: Non-interventional (OTHER).

Who is sponsoring clinical trial NCT03331393?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03331393 being conducted?

This trial has 7 study locations across California, Georgia, Idaho, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03331393's enrollment target sits among peer trials

265 70th of 197 higher than 128 of 197 other Rheumatoid Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05443126 · 265 participants · Phase 1

    A Study of EP0031 in Patients With Advanced RET-altered Malignancies

  • NCT05470491 · 265 participants · Phase 1

    Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

  • NCT07301905 · 265 participants · NA

    Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI

  • NCT07470853 · 265 participants · Phase 1

    A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03331393, the US trial registry maintained by the National Library of Medicine. NCT03331393 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.